<DOC>
	<DOCNO>NCT02518087</DOCNO>
	<brief_summary>Our project intend reduce acute kidney injury non emergent cardiac surgery ( AKI-CS ) patient use increased adsorption membrane ( OXIRIS® ) connect cardiopulmonary bypass ( CPB ) circuit , besides evaluate inflammatory response quantify inflammatory mediator cardiac surgery CPB . Our study randomize control multicentre trial include recruit centre long experience cardiac surgery CPB . The primary endpoint project evaluate ability OXIRIS® reduce incidence AKI-CS patient undergo non emergent cardiac surgery CPB . With goal reduce 10 % ( 15 5 % ) risk AKI-CS first postoperative week sample size 340 patient calculate . Secondary endpoint two ; first , evaluate effect use OXIRIS® survival , clinical course removal capacity cytokine lipopolysaccharide ( LPS ) CPB ; second , assess predictive value AKI-CS new biomarkers , uNAD ( urinary nicotinamide adenine dinucleotide ) .</brief_summary>
	<brief_title>Increased Adsorption Membranes During Cardiopulmonary Bypass</brief_title>
	<detailed_description>After informed consent , patient randomize CPB-OXIRIS® , PrismafleX eXeed™ II ( Baxter Gambro ) OXIRIS® set irrigate saline preparation irrigation CPB circuit . PrismafleX eXeed™ II ( Baxter Gambro ) OXIRIS® set connect CPB circuit . Blood flow 200-250 ml/min derive CPB circuit PrismafleX eXeed™ flow OXIRIS® membrane . Flow , pressure alarm setting control PrismafleX eXeed™ independently CPB circuit . OXIRIS® membrane employ adsorption ( neither convection diffusion perform ) CPB time . Using CPB flow , patient require venous catheter access neither change CPB normal setting . All blood sample collect study obtain CPB circuit central venous catheter ( standard cardiac surgery protocol ) . During CPB time besides ordinary cardiac surgery assistance team , supplementary CRRT expert team present patient randomize CPB-OXIRIS® . Blood sample variable equally collect register control group ( CPB-Standard ) modification CPB standard practice . Adverse event report ( less 24 hour severe ) sponsor centre properly evaluate . If severe adverse event ( SAE ) finally evaluate study board relate intervention arm , urgent notification health authority must proceed study interrupted decision . Investigators warrant correct protocol application . Study data review external monitoring committee clinical assay research central unit ( UCICEC - IDIBELL ) . Monitors contrast register data collection data form ( CDF ) data patient ' medical record . All patient ' medical record indefinitely save electronic format review necessary . Efficacy Assessments ( What data collected/utilized ? ) : 1 . Registered variable follow-up . Renal function relate parameter Plasma creatinine urine output register baseline , prior CPB , ICU admission , 6 hour ,12 hour , 24h postCBP every 24h first week cardiac surgery order evaluate postcardiac surgery acute kidney injury base AKIN criterion ( AKIN criterion Kidney inter. , Suppl . 2012 ; 2 : 1-138 . ) Urinary NAD ( uNAD ) also quantify ICU admission . Renal function check hospital discharge . Inflammatory response parameter Interleukin-1β ( IL-1β ) , tumor necrosis factor alpha ( TNF-α ) , monocyte chemotactic protein-1 ( MCP-1 ) , interleukin-6 ( IL-6 ) , interleukin-8 ( IL-8 ) , interleukin-10 ( IL-10 ) , interleukin-18 ( IL-18 ) , complement 5a ( C5a ) , high mobility bind protein 1 ( HMBP-1 ) , RANTES , GRO-alpha , leukocytes count , lactate , D-dimer , free plasma hemoglobin , HO-1 , free iron Lipopolysaccharide ( LPS ) level determine plasma.These determination measure baseline ( 0 hour ) , time T1 ( end CPB ) , T2 ( ICU admission ) T3 ( 24 hour ICU admission ) . Ordinary laboratory parameter Plasmatic urea , potassium , albumin , magnesium , phosphate , glucose , sodium , chloride , AST , ALT , blood cell count coagulation time determine follow ordinary cardiac surgery protocol ( every 8 hour first 24h ) . Clinical respiratory parameter Hemodynamic respiratory parameter register every hour . Arterial venous blood gas arterial lactate determine every 8 hour first 24 hour . Temperature , heart rate , arterial blood pressure ( systolic , diastolic , mean ) , central venous pressure , vasopressor and/or inotrope dose register surgery ICU accord standard protocol . Demographic clinical record data Age , gender , weight , height , relevant clinical record , previous chronic medication , type cardiac surgery , surgery time , time CPB , surgical complication , blood transfusion surgery , prognostic score ( SOFA , APACHE II SAPS II ) , ICU stay , hospital stay . Clinical outcome ( survival discharge , 28 90 day ) renal outcome ( renal function , RRT requirement ) . 2 . Techniques . Lipopolysaccharide ( LPS ) LPS plasmatic concentration measure use Limulus amebocyte lysate ( LAL ) test ( Levin , J , et al . Thrombosis Et Diathesis Haemorrhagica . 1968 ; 19:186 ) . This technique perform LAL proteolytic factor activate LPS . Life Technologies kit use ( Thermo Fischer Scientific ) . NAD Urinary blood level NAD determine 0 hour time T1 ( end CPB ) , T2 ( ICU admission ) , T3 ( 24 hour ICU admission ) apply multiplexed mass spectrometry technique . Cytokine analysis IL-1 , IL-6 , IL-8 , IL-10 , IL-18 , TNFα , MCP-1 , HMBP-1 , RANTES , GROα quantification perform multiplex new technology . MILLIPLEX ( Millipore ) magnetic ball system use . Statistical Methods ( analyze primary &amp; secondary endpoint ) : Statistical analysis do statistic investigator wo n't role patient selection , randomization , follow . SPSS v. 20.0 statistical analysis use . Variable distribution study logarithmic transformation use variable n't present normal distribution , presumably cytokine LPS level . Univariate analysis compare clinical , demographic , biochemical , metabolic , hemodynamic respiratory baseline variable arm ( CPB-OXIRIS® CPB-Standard ) , do two-tailed test continuous variable chi-square test categorical variable . Variables determine several time ( T0 , T1 , T2 , T3 ) analyse use one-way repeat measure ANOVA test order demonstrate difference arm . Multivariate analysis complete control clinically relevant confounding variable well discover baseline difference . According hypothesis dependent variable study investigator use survival analysis ( study AKI-CS within first week postsurgery ) Cox regression model , hierarchic multiple linear regression model dependent variable continuous ( example , uNAD ) . Arm intervention ( CPB-OXIRIS® , CPB-Standard ) consider main independent variable add control independent variable . As study measure cytokine LPS level four different moment ( T0 , T1 , T2 , T3 ) , order maximize statistical power reduce control variable number , area curve ( AUC ) calculate every cytokine LPS first 24 hour . Due statistical maneuver investigator obtain continuous variable represent cytokine-LPS level biochemical study period ( 24 hour ) . To evaluate arm intervention improvement term efficacy safety could relate cytokine and/or LPS level first 24 hour , mediation complementary analysis perform consider cytokine-LPS ( represent AUC ) mediator independent variable ( intervention arm ) effect study .</detailed_description>
	<mesh_term>Acute Kidney Injury</mesh_term>
	<mesh_term>Systemic Inflammatory Response Syndrome</mesh_term>
	<criteria>Patients 18 year old . Non emergent cardiac surgery require CPB . Written informed consent patient legal surrogate . Immunosuppressive treatment steroid ( prednisone &gt; 0.5 mg/kg/day equivalent ) . Autoimmune disorder . Transplant receptor . Advanced Chronic Kidney Disease ( CKD 4 5 ) . Renal replacement therapy last 90 day . Documented intolerance study device . Inclusion ongoing study within last 30 day . Pregnancy . Coexisting illness high probability death ( inferior 6 month ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>CPB</keyword>
	<keyword>OXIRIS®</keyword>
	<keyword>AKI</keyword>
	<keyword>SIRS</keyword>
	<keyword>Cytokines</keyword>
	<keyword>LPS</keyword>
</DOC>